Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1)

Phase 2 Completed 121 enrolled Astellas Pharma Global Development, Inc.

RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to evaluate the safety and efficacy of avacincaptad pegol intravitreal injection compared to Sham in participants with autosomal recessive Stargardt disease 1 (STGD1).

Timeline

Start: 2018-01-12
Primary completion: 2025-03-31
Completion: 2025-03-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Avacincaptad Pegol	Aptamer	—	Intravitreal

Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1)

Summary

Timeline

Drugs

Indications